BIOMAT Database Logo BIOMAT Database Logo

Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008-2011. 2012

Andrew Walkty, and Melanie Baxter, and Heather Adam, and James A Karlowsky, and Philippe Lagacé-Wiens, and Daryl J Hoban, and George G Zhanel
Department of Medicine, Health Sciences Centre, Winnipeg, Manitoba, Canada. awalkty@mts.net

Broth microdilution (Clinical and Laboratory Standards Institute) was used to evaluate the antimicrobial susceptibility of 1549 Pseudomonas aeruginosa clinical isolates collected in Canada between January 2008 and October 2011. The percentage of isolates susceptible was as follows: amikacin 92.0%, ceftazidime 83.5%, ciprofloxacin 74.3%, colistin 93.4%, gentamicin 76.8%, meropenem 82.7%, and piperacillin-tazobactam 83.6%. Antimicrobial susceptibility did not change significantly between 2008 and 2011, with the exception of increasing susceptibility to gentamicin (P < 0.0001).

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002170 Canada The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.
D006761 Hospitals Institutions with an organized medical staff which provide medical care to patients. Hospital
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

Andrew Walkty, and Melanie Baxter, and Heather Adam, and James A Karlowsky, and Philippe Lagacé-Wiens, and Daryl J Hoban, and George G Zhanel
In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).
June 2011, Antimicrobial agents and chemotherapy,
Andrew Walkty, and Melanie Baxter, and Heather Adam, and James A Karlowsky, and Philippe Lagacé-Wiens, and Daryl J Hoban, and George G Zhanel
Genomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil.
July 2023, Pathogens (Basel, Switzerland),
Andrew Walkty, and Melanie Baxter, and Heather Adam, and James A Karlowsky, and Philippe Lagacé-Wiens, and Daryl J Hoban, and George G Zhanel
Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian intensive care units as part of the Canadian National Intensive Care Unit study.
June 2008, Diagnostic microbiology and infectious disease,
Andrew Walkty, and Melanie Baxter, and Heather Adam, and James A Karlowsky, and Philippe Lagacé-Wiens, and Daryl J Hoban, and George G Zhanel
Species distribution and antifungal susceptibility of invasive Candida isolates from Canadian hospitals: results of the CANWARD 2011-16 study.
August 2019, The Journal of antimicrobial chemotherapy,
Andrew Walkty, and Melanie Baxter, and Heather Adam, and James A Karlowsky, and Philippe Lagacé-Wiens, and Daryl J Hoban, and George G Zhanel
Comparison of the antimicrobial susceptibility patterns of Pseudomonas aeruginosa isolates from two hospitals.
December 1986, The Journal of the Oklahoma State Medical Association,
Andrew Walkty, and Melanie Baxter, and Heather Adam, and James A Karlowsky, and Philippe Lagacé-Wiens, and Daryl J Hoban, and George G Zhanel
Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD).
May 2013, The Journal of antimicrobial chemotherapy,
Andrew Walkty, and Melanie Baxter, and Heather Adam, and James A Karlowsky, and Philippe Lagacé-Wiens, and Daryl J Hoban, and George G Zhanel
Heterogeneous Antimicrobial Susceptibility Characteristics in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients.
January 2018, mSphere,
Andrew Walkty, and Melanie Baxter, and Heather Adam, and James A Karlowsky, and Philippe Lagacé-Wiens, and Daryl J Hoban, and George G Zhanel
Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study.
March 2011, Diagnostic microbiology and infectious disease,
Andrew Walkty, and Melanie Baxter, and Heather Adam, and James A Karlowsky, and Philippe Lagacé-Wiens, and Daryl J Hoban, and George G Zhanel
Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).
November 2010, Antimicrobial agents and chemotherapy,
Andrew Walkty, and Melanie Baxter, and Heather Adam, and James A Karlowsky, and Philippe Lagacé-Wiens, and Daryl J Hoban, and George G Zhanel
In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008.
November 2009, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!